Mental Health DailyResearch. Evidence. Perspective.Published research on alzheimers disease.
Lecanemab blood biomarkers may rebound much faster than amyloid PET after treatment stops: a 2026 PK/PD model estimated that half of the Aβ42/40 treatment effect is lost within 0.5 years, co…
Read articleA 2026 TADPOLE modeling study reported that a sequential neural process with normalizing flows predicted future Alzheimer diagnostic stage with mAUC 0.965 ± 0.006, ahead of the authors’ earl…
Read articleA 2026 ALZAN memory-clinic cohort found that cerebrospinal-fluid alpha-synuclein seed amplification assay detected 19 of 20 Lewy body dementia cases, with 95% sensitivity and 93.5% specifici…
Read articleA 2026 multi-cohort Alzheimer’s disease study found that MRI radiomics from the hippocampus and amygdala linked plasma pTau217 and smell identification to cognitive impairment — with more ad…
Read articleA 2026 Acta Neuropathologica study found that oligomeric tau was linked to early nuclear lamina disruption in Alzheimer’s disease tissue, PS19 tauopathy mice, and human induced pluripotent s…
Read articleA 2026 mechanistic Alzheimer’s study found that suppressing NDST3 shifted lysosomal pH in APP695Swe neuronal cells from 5.6 back below 5.0, then reduced amyloid-β, MAPT/tau pathology, neuron…
Read articleA 2026 ADNI study reported 85.23% accuracy for ANA-GNN, a graph neural network that combined structural MRI regional features with clinical variables to classify cognitively normal controls,…
Read article
